As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.
Six killed in shooting in main square of Krakow, police say
Russian strikes hit power facilities around Kyiv, damage major bridge
Heavy rains flood tents housing displaced Palestinians, aid shortages worsen
Qatar says its mediation efforts between US and Iran continue to prevent escalation
Pope Leo urges South America to bridge divides on Uruguay-Argentina border
